Analysis of US Patent 6,875,445: Scope, Claims, and Patent Landscape

What does US Patent 6,875,445 cover?

US Patent 6,875,445, issued on April 5, 2005, encompasses a method of treating diseases using a specific class of compounds. It claims the formulation and application of a pharmaceutical composition containing a particular anticancer agent. The patent is assigned to Eli Lilly and Company. The scope primarily revolves around the use of a substituted pyrazolopyrimidine compound for inhibiting kinases involved in tumor progression.

What are the specific claims outlined in the patent?

Claim Set Overview

Claim 1: A method of inhibiting kinase activity in a mammal comprising administering an effective amount of a compound with the structure of a pyrazolopyrimidine derivative, specifically where substituents R1-R4 are defined within a certain chemical space.
Claim 2: The method of claim 1, wherein the kinase inhibited is selected from the group consisting of RAF, VEGFR, and PDGFR kinases.
Claim 3: The method of claim 1, where the composition is administered orally.
Claim 4: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
Claim 5: A method of treating cancer in a patient, comprising administering the compound of claim 1 in an amount effective to inhibit tumor growth.

Key Claim Features

Broad chemical scope defined by a core structure with variable substituents.
Focus on kinase inhibition, particularly targeting enzymes involved in angiogenesis and tumor proliferation.
Claims extend to both method of treatment and pharmaceutical compositions.

Claim Strategy and Limitations

The claims are predominantly method claims with an auxiliary focus on compositions. The chemical scope covers a wide class of compounds within a defined structure, allowing for potential patent thickets and generic challenge. While the claims specify kinase targets and administration routes, they lack narrower, process-specific limitations which would strengthen enforceability against non-infringing variants.

How extensive is the patent landscape related to US 6,875,445?

Related Patent Families and Cited Art

Cited Patents: Over 30 prior patents are cited, including references to kinase inhibitors, pyrazolopyrimidine derivatives, and cancer therapies.
Family Members: The patent has international counterparts filed via PCT and in jurisdictions such as Europe (EP), Japan (JP), and Canada (CA), with key family members published between 2003-2007.
Commercial Landscape: Multiple pharmaceutical companies own patents targeting similar kinase inhibitor structures, with notable overlaps in the pyrazolopyrimidine class, including GSK, Novartis, and Pfizer.

Recent Developments

Patents filed from 2010-2020 expand on the core structure, focusing on specific kinase selectivity and improved pharmacokinetics.
Patent filings from Chinese and Indian entities indicate a growing interest in this chemical space, with numerous patent publications from 2015 onward.

Litigation and Patent Challenges

No publicly available litigation directly referencing US Patent 6,875,445.
Patent life runs until 2025, with possible extensions through patent term adjustments.
Challenges to validity are limited due to the patent’s reliance on well-established kinase inhibitors, yet prior art references question the novelty of some claimed substitutions.

How does US Patent 6,875,445 compare to other kinase inhibitor patents?

Patent	Assignee	Filing Year	Key Focus	Scope	Patent Term (Expiration)
US 6,875,445	Eli Lilly	2002	Pyrazolopyrimidine kinase inhibitors	Broad chemical scope targeting multiple kinases	2025 (patent term)
US 6,645,877	GSK	2000	RAF kinase inhibitors	Narrower chemical modifications with high selectivity	2023-2025 (may vary)
US 7,029,716	Novartis	2004	VEGFR inhibitors	Focus on anti-angiogenic agents	2022-2024
US 8,289,987	Pfizer	2008	Multi-kinase inhibitors	Specific combinations targeting solid tumors	2026

US Patent 6,875,445 has a relatively broad claim set, which increases its blocking potential but also exposes it to validity challenges based on prior kinase inhibitor disclosures.

Key Takeaways

The patent's broad chemical claims cover multiple pyrazolopyrimidine derivatives for kinase inhibition in cancer therapy.
The patent landscape involves numerous filings, with overlapping chemical structures and target kinases, signifying a competitive space.
Technical limitations like the broad scope pose potential challenges over patent validity, especially considering prior art.
The patent remains enforceable until 2025, with active competition from subsequent patents focusing on selectivity and pharmacokinetic enhancement.
Eli Lilly’s patent strategy emphasizes broad coverage, which could influence both licensing opportunities and litigation risks.

FAQs

1. What are the main intellectual property threats to the patent?
Prior art references involving kinase inhibitors with similar structures could challenge the patent’s novelty and inventive step. Patent filing strategies by competitors may also narrow or design around the claims.

2. Are there any active litigations involving this patent?
No publicly available cases directly challenge US Patent 6,875,445.

3. How does the claim scope impact generic development?
The broad chemical claims may delay generic entry if upheld, but overlap with existing prior art could lead to invalidation.

4. Which kinases are targeted in this patent?
RAF, VEGFR, and PDGFR kinases are explicitly claimed targets.

5. What is the potential expiration date for this patent?
It is set to expire in 2025, unless extended through patent term adjustments or at-risk marketing.

References

[1] U.S. Patent Office. (2005). US Patent 6,875,445.
[2] WIPO. (2002). Patent Family Data for US 6,875,445.
[3] PatentScope. (2023). Patent Search Results – Kinase Inhibitors.
[4] FDA. (2022). Approved Kinase Inhibitors for Cancer.
[5] Espacenet. (2023). Patent Landscape of Pyrazolopyrimidine Derivatives.

Details for Patent: 6,875,445

Summary for Patent: 6,875,445